Scryb Inc. Forum: Community User: Philipp85

Spekuliert nicht zu hoch hier! Macht zumindest Teilgewinnmitnahmen. Auf 0.20 Cent warten kann funktionieren. Die immer währende Beobachtung hier und Erfahrung ist hslt eine andere.

Da kann ich @ Rocky nur zustimmen war die ganzen jahre hier so

Leute! Das geht schnell wieder runter! Macht Eure Gewinne

Hab mir das Produkt angeschaut, klinkt wirklich vielversprechend

Will keine falschen Prognosen abgeben, aber 1,9 denke ich ist möglich

Denke wenn die amis die nachrichten lesen gehts nochmal hoch

Bin auch rein

Bin nach dem ersten Post heute morgen auch rein, ich spekuliere auf über 0,20 € heute

Wann ist das gestern bekanntgegeben worden? Nach Börsenschluss?

Meinst du, es tut sich was um 15:30 wenn die Amis kommen?

Bin grad noch rein

Wer ist hier investiert?

Heute gelesen.... mal gespannt was passiert Relay Medical (WKN: A2JQR0) gibt bekannt, dass eine verbindliche Absichtserklärung mit Proprietary Innovation Labs Inc. über den exklusiven Verkauf und Vertrieb von diagnostischen Schnelltests für COVID-19 unterzeichnet wurde. Im Rahmen der Vereinbarung erwirbt man die exklusiven weltweiten Rechte an der COVID-19-Produktlinie von Proprietary Innovation Labs, einschließlich CE-zugelassener Schnelldiagnosetests für Antikörper und Antigen-Lateral-Flow (RDT). Die Tests sind einfach zu bedienen, erfordern keine zusätzliche Ausrüstung und verfügen über eine hohe Diagnosegenauigkeit. Die Ergebnisse sind in nur drei Minuten verfügbar. Derzeit können bis zu 25 Millionen Tests pro Monat hergestellt werden.

Relay Medical Corp Symbol RELA Shares Issued 125,080,164 Close 2020-11-09 C$ 0.21 Recent Sedar Documents View Original Document Relay enters binding LOI for rights to COVID tests 2020-11-09 17:39 ET - News Release Mr. Yoav Raiter reports RELAY MEDICAL SUBSIDIARY SIGNS BINDING LOI FOR RIGHTS TO COVID-19 RAPID ANTIGEN AND ANTIBODY TESTS Relay Medical Corp. has entered into a binding letter of intent with Proprietary Innovation Labs Inc. (PIL) relating to the exclusive sale and distribution of rapid diagnostic tests for COVID-19. The binding LOI was signed Nov. 9, 2020. Under the terms of the LOI agreement, Relay Medical's diagnostics subsidiary, HemoPalm Corp., will acquire the exclusive global rights excluding China to Proprietary Innovation Labs' COVID-19 product line, including CE (Conformite Europeenne)-approved antibody and antigen lateral flow rapid diagnostic tests (RDT). PIL has developed both antigen and antibody tests for the SARS-CoV-2 virus with its manufacturing partners. These test kits are suitable for point-of-care testing and are based on lateral flow chromatographic immunoassay for qualitative detection. The tests are easy to use, require no extra equipment and possess high-diagnostic accuracy, and results are available in as few as 10 minutes. Test kits are packaged with all necessary materials to run the test, which is read visually in a manner like pregnancy-test sticks. Through its contract manufacturing facilities, PIL can produce over 25 million tests per month. "Screening, testing and tracing is absolutely crucial to the effective management of day-to-day life during a global pandemic like COVID-19. This is a global infection, and management will require a plethora of solutions, technologies and protocols to allow people to return back to school, work and recreation with confidence. Even after a worldwide mass deployment of a vaccine, continuous testing support will likely be needed for a significant period of time," said Yoav Raiter, chief executive officer, Relay Medical. "The partnership between Relay and PIL is as exciting as it is important. We are now able to offer a complete holistic solution using our antigen and antibody tests in tandem with Relay's cloud-based verification, tracking and reporting technology. This partnership is an exciting moment for PIL and their initiatives to combat the COVID-19 pandemic," said Richard Waters, president, Proprietary Innovation Labs. According to PIL, the clinical sensitivity (confirmed positive with a PCR nucleic test) for the antigen tests is 95.0 per cent, and the clinical specificity (confirmed negative with a PCR nucleic test) is 99.6 per cent. For the PIL antibody tests, the clinical sensitivity is 93.3 per cent for samples collected after the onset of symptoms with a clinical specificity of 99.0 per cent. These tests can help health care professionals identify active SARS-CoV-2 infections (antigen) and immune responses (antibody) in people suspected to be carrying the virus or confirming previously exposure, allowing for better patient management, as well as more effective use of health care resources. The company believes that rapid antibody tests can play an important role in characterizing a vaccine-induced immune response, meaning that these tests could be used to evaluate the effectiveness of COVID-19 vaccines when they are deployed. Early detection using rapid antigen tests can also provide further protection to front line workers as a possible screening tool for the identification of COVID-19 amongst front line health care workers and employees. The PIL antigen and antibody detection kits have CE certification, meaning that the manufacturer and products have met European Union declaration of standards for health, safety and environmental protection, allowing these products to be sold within the 22 countries in the European economic area. PIL and Relay will consider applying to submit these tests for further approvals to the Food and Drug Administration for emergency use authorization (EUA) and to Health Canada for approval under the medical devices interim order (IO). Relay and PIL intend to source additional clients for the products, which will be manufactured pursuant to PIL's guidelines and protocols and will consist of an identifiable exclusive brand to be mutually agreed by the parties. Relay and PIL will share the profits earned from the sale of the products, with the party sourcing the purchaser earning 60 per cent and the other party earning 40 per cent. The company and PIL plan to sell these kits in all countries where the kits have been approved for sale. Relay and PIL have agreed to negotiate and execute a definitive agreement, setting out the terms of its relationship in greater detail, which will contain the terms, covenants, representations, warranties and indemnities as set forth in the letter of intent, and such other terms as agreed by the parties. The letter of intent will terminate if a definitive agreement has not been entered into by the parties within 45 days following a due diligence process. Relay is issuing 400,000 common shares to the shareholders of PIL as consideration of the agreement. The clinical performance of the PIL antigen tests was evaluated compared with RT-PCR positive cases at one hospital.

@DonBörsianer Was macht Produktion und Verkauf? Bestimmt schon viele Millionen, oder. Muss doch ein Klacks sein, diese einfachen Schnelltests zu produzieren,sofern sie einer will und sie was taugen. 🤔🙄

@530684: Man, bzgl. der 'leeren' Versprechen' bis jetzt bist du garantiert nicht der Einzige....